Intrahepatic cholestasis of pregnancy (ICP) affects roughly 3 in every 100 pregnancies worldwide, based on a large systematic review and meta-analysis. That makes it one of the more common liver conditions specific to pregnancy, though your individual risk depends heavily on where you live and your ethnic background. If you’ve been diagnosed or suspect you have it, you’re far from alone.
Global and Regional Rates
The overall pooled incidence of ICP is 2.9% of pregnancies globally. But rates vary dramatically by region. South America and Asia have the highest rates, while North America and Oceania have the lowest. In the Americas overall, the rate sits around 1.6%. In the Western Pacific region it’s 3.4%, and in Europe about 2.5%.
Within the United States specifically, reported rates range widely, from as low as 0.32% in some studies to as high as 5.6% in others. This spread reflects differences in the populations studied, how aggressively doctors test for it, and which diagnostic thresholds are used. Most estimates for Central and Western Europe and North America land between 0.4% and 1% of pregnancies.
Some Populations Have Much Higher Rates
Certain ethnic groups and geographic populations have historically faced far higher ICP rates. In Chile and Bolivia, the condition once affected up to 14% of all pregnancies before 1975. Among the Araucanos Indians of Chile, the rate reached 27.6%, and among the Aimara Indians of Bolivia, 13.8%. These numbers have dropped significantly in recent decades to less than 2%, likely due to dietary and environmental changes, though the genetic predisposition remains.
Scandinavian and Baltic countries also see elevated rates, with ICP occurring in up to 2% of pregnancies. If you have South American Indigenous, Scandinavian, or South Asian ancestry, your risk is higher than average.
How ICP Typically Presents
The hallmark symptom is itching that usually starts in the late second or early third trimester, though cases as early as 8 weeks have been documented. The itch typically begins on the abdomen, then spreads across the trunk, and very characteristically affects the palms of the hands and soles of the feet. It often starts as intermittent and becomes constant over time. There’s usually no rash, which is one way it differs from other pregnancy-related skin conditions.
Diagnosis relies on that clinical picture of itching combined with a blood test measuring total serum bile acids. A level at or above 10 micromol/L is the standard diagnostic threshold, and this test is both 91% sensitive and 93% specific for ICP. Liver enzymes (ALT and AST) are often mildly elevated but typically stay within twice the normal range for pregnancy.
Why Bile Acid Levels Matter
Not all ICP carries the same level of risk. Doctors classify severity based on how high your bile acid levels climb, and this directly affects what happens next in your care.
- Mild ICP (10 to 39 micromol/L): The most common form. The risk of serious complications is relatively low, and pregnancy can often continue to 39 weeks or beyond after weighing the benefits and risks.
- Severe ICP (40 to 99 micromol/L): Carries a meaningfully higher risk of preterm birth and stillbirth. Guidelines recommend planning delivery between 36 and 38 weeks.
- Extremely severe ICP (100 micromol/L or above): The risk of stillbirth rises significantly. Delivery at 36 weeks is recommended, and earlier delivery may be considered if symptoms are uncontrolled, liver function is worsening, or there’s a prior history of ICP-related stillbirth.
The relationship between bile acid levels and fetal risk is dose-dependent: the higher the levels, the greater the concern. A large 2019 meta-analysis found that the risk of stillbirth is primarily elevated in those with levels above 100 micromol/L, which has helped reassure patients with milder forms that their risk, while real, is much lower.
Risks to the Baby
ICP has been associated with preterm birth (both spontaneous and medically induced), meconium-stained amniotic fluid, signs of fetal distress, and stillbirth. The stillbirth risk is the most concerning and is the main reason doctors monitor bile acid levels closely and plan earlier delivery when levels are high. The risk is highest after 37 weeks in unmanaged cases, which is why timing of delivery is such a central part of ICP care.
Treatment and What to Expect
The primary medication used for ICP is ursodeoxycholic acid (often called “urso” or UDCA), a bile acid that helps reduce the load of toxic bile acids in your bloodstream. Its effect on itching is modest. Studies show it reduces pruritus scores, but not always to a degree that feels dramatically better. Where it appears more impactful is in reducing the combined risk of stillbirth and preterm birth. One analysis found that for every 15 women treated with UDCA, one case of stillbirth or preterm birth was prevented.
Beyond medication, the cornerstone of management is regular monitoring of bile acid levels and planning the timing of delivery based on severity. If you’re diagnosed with ICP, expect more frequent blood draws and closer fetal monitoring in the final weeks of pregnancy. The itching itself resolves rapidly after delivery, typically within days.
Recurrence in Future Pregnancies
If you’ve had ICP once, there’s a substantial chance it will return. Reported recurrence rates range from 40% to 90% in the medical literature. A recent study of 104 patients with ICP found that 44% experienced it again in a subsequent pregnancy. This means that while recurrence is common, it’s not inevitable. Some women have ICP in one pregnancy and not the next, and severity can differ between pregnancies. Knowing your history allows your care team to start monitoring bile acids earlier in future pregnancies, often catching it sooner if it does return.